These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 29696458)

  • 1. Methodological problems in the method used by IQWiG within early benefit assessment of new pharmaceuticals in Germany.
    Herpers M; Dintsios CM
    Eur J Health Econ; 2019 Feb; 20(1):45-57. PubMed ID: 29696458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Patient-relevant outcomes and surrogates in the early benefit assessment of drugs: first experiences].
    Kvitkina T; ten Haaf A; Reken S; McGauran N; Wieseler B
    Z Evid Fortbild Qual Gesundhwes; 2014; 108(8-9):528-38. PubMed ID: 25523852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Health-related quality of life: a pivotal endpoint in benefit assessment of medical procedures].
    Bullinger M; Blome C; Sommer R; Lohrberg D; Augustin M
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Mar; 58(3):283-90. PubMed ID: 25589357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early benefit assessment of pharmaceuticals in Germany: manufacturers' expectations versus the Federal Joint Committee's decisions.
    Fischer KE; Stargardt T
    Med Decis Making; 2014 Nov; 34(8):1030-47. PubMed ID: 25149822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Information on new drugs at market entry: retrospective analysis of health technology assessment reports versus regulatory reports, journal publications, and registry reports.
    Köhler M; Haag S; Biester K; Brockhaus AC; McGauran N; Grouven U; Kölsch H; Seay U; Hörn H; Moritz G; Staeck K; Wieseler B
    BMJ; 2015 Feb; 350():h796. PubMed ID: 25722024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Challenges for clinical trials in oncology within the scope of early benefit assessment of drugs].
    Lange S
    Z Evid Fortbild Qual Gesundhwes; 2015; 109(6):417-30. PubMed ID: 26474646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early benefit assessment (EBA) in Germany: analysing decisions 18 months after introducing the new AMNOG legislation.
    Ruof J; Schwartz FW; Schulenburg JM; Dintsios CM
    Eur J Health Econ; 2014 Jul; 15(6):577-89. PubMed ID: 23771769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early benefit assessment of new drugs in Germany - results from 2011 to 2012.
    Hörn H; Nink K; McGauran N; Wieseler B
    Health Policy; 2014 Jun; 116(2-3):147-53. PubMed ID: 24472328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of the target population in early benefit assessments in Germany: challenges for non-small-cell lung cancer.
    Ten Thoren C; Balg C; Gibbert J; Mostardt S; Ripoll M; Schierbaum D; Schiller S; Schwalm A
    Eur J Health Econ; 2020 Aug; 21(6):881-893. PubMed ID: 32236766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Four years of early benefit assessment of new drugs in Germany: a qualitative study on methodological requirements for quality of life data.
    Blome C; Augustin M; Metin H; Lohrberg D
    Eur J Health Econ; 2017 Mar; 18(2):181-193. PubMed ID: 26837412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Drug assessment: IQWiG, G-BA, and an international comparison].
    Glaeske G
    Internist (Berl); 2016 Jan; 57(1):94-101. PubMed ID: 26502888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Confirmatory versus explorative endpoint analysis: Decision-making on the basis of evidence available from market authorization and early benefit assessment for oncology drugs.
    Niehaus I; Dintsios CM
    Health Policy; 2018 Jun; 122(6):599-606. PubMed ID: 29605527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methodological approach to determine minor, considerable, and major treatment effects in the early benefit assessment of new drugs.
    Skipka G; Wieseler B; Kaiser T; Thomas S; Bender R; Windeler J; Lange S
    Biom J; 2016 Jan; 58(1):43-58. PubMed ID: 26134089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Benefit assessment of drugs].
    Kaiser T; Vervölgyi V; Wieseler B
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Mar; 58(3):232-9. PubMed ID: 25566842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A theoretical and empirical investigation into the willingness-to-pay function for new innovative drugs by Germany's health technology assessment agency (IQWiG).
    Gandjour A
    Health Serv Manage Res; 2013 Nov; 26(4):103-9. PubMed ID: 25595007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of validated and nonvalidated surrogate endpoints in two European Medicines Agency expedited approval pathways: A cross-sectional study of products authorised 2011-2018.
    Schuster Bruce C; Brhlikova P; Heath J; McGettigan P
    PLoS Med; 2019 Sep; 16(9):e1002873. PubMed ID: 31504034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biometrical issues in the analysis of adverse events within the benefit assessment of drugs.
    Bender R; Beckmann L; Lange S
    Pharm Stat; 2016 Jul; 15(4):292-6. PubMed ID: 26928768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Health-Related Quality of Life in the Context of Early Benefit Assessment of Drugs According to § 35a of the German Social Code Book V: A Challenging Endpoint for all the Involved Stakeholders].
    Bender H; Dintsios CM
    Gesundheitswesen; 2018 Feb; 80(2):132-143. PubMed ID: 27846666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.